We are live on ! Find out more
KXA

KPCB XV Associates Portfolio holdings

AUM $35.8M
1-Year Est. Return 57.59%
This Fund
S&P 500
This Quarter Est. Return
-2.75%
1 Year Est. Return
-57.59%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$35.8M
AUM Growth
-$18.4M
Cap. Flow
-$15.3M
Cap. Flow %
-42.79%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$15.3M
2
AUGX
Augmedix, Inc. Common Stock
AUGX
+$1K

Sector Composition

Rank Sector Weight
1 Healthcare 63.34%
2 Technology 36.66%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPT
1
DELISTED
RAPT Therapeutics
RAPT
$15.6M 43.54%
81,066
-81,067
-50% -$15.3M
TWLO icon
2
Twilio
TWLO
$31.2B
$13.1M 36.67%
190,047
– –
ATRA icon
3
Atara Biotherapeutics
ATRA
$73.7M
$7.09M 19.79%
75,066
– –
AUGX
4
DELISTED
Augmedix, Inc. Common Stock
AUGX
– –
-708
Closed -$1K

Similar funds

ALFIA
Accel Leaders Fund II Associates Palo Alto, California $36.6M AUM 58.14% 1-Year Est. Return
KCGDR
Kiron Capital Gestao de Recursos Sao Paulo, Brazil $36.9M AUM 49.85% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
FCOMV
Foresite Capital Opportunity Management V Larkspur, California $33.3M AUM 47.04% 1-Year Est. Return
SEM
Spectrum Equity Management San Francisco, California $39.1M AUM 63.69% 1-Year Est. Return
MCMI
Matrix China Management III Grand Cayman, Cayman Islands $39.3M AUM
LCM
LH Capital Markets New York $39.4M AUM 14.61% 1-Year Est. Return

KPCB XV Associates's Q3 2022 Portfolio in Review

As of Q3 2022, KPCB XV Associates held 4 positions worth $35.8M, down 34% from $54.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

KPCB XV Associates withdrew a net $15.3M in Q3 2022, closing 1 position and reducing 1 holding. Its most notable exit was Augmedix, Inc. Common Stock, an estimated $1K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 71% a quarter earlier, followed by Technology and Industrials.

  • KPCB XV Associates's biggest Q3 2022 reduction was RAPT Therapeutics, cutting an estimated $15.3M.
  • KPCB XV Associates fully exited Augmedix, Inc. Common Stock in Q3 2022, selling an estimated $1K.
  • KPCB XV Associates's ten largest holdings make up 100% of its $35.8M portfolio in Q3 2022.
  • KPCB XV Associates opened 0 new positions and closed 1 in Q3 2022.
  • KPCB XV Associates's portfolio value fell 34% quarter-over-quarter to $35.8M.

Based on KPCB XV Associates's 13F filing for Q3 2022, filed 26 Oct 2022.